Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Carcinogenesis. Author manuscript; available in PMC 2009 January 1.
Published in final edited form as:
PMCID: PMC2292458

Survivin repression by p53, Rb, and E2F2 in normal human melanocytes


The inhibitor of apoptosis (IAP) protein Survivin is a dual mediator of apoptosis resistance and cell cycle progression, and is highly expressed in cancer. We have previously shown that Survivin is upregulated in melanoma compared to normal melanocytes, is required for melanoma cell viability, and that melanocyte expression of Survivin predisposes mice to UV-induced melanoma and metastasis. The mechanism(s) of Survivin upregulation in the course of melanocyte transformation, and its repression in normal melanocytes, however, has not been clearly defined. We show here that p53 and Rb, at basal levels and in the absence of any activating stimuli, are both required to repress survivin transcription in normal human melanocytes. Survivin repression in melanocytes does not involve alterations in protein stability or promoter methylation. p53 and Rb (via E2Fs) regulate Survivin expression by direct binding to the survivin promoter; p53 also affects Survivin expression by activating p21. We demonstrate a novel role for E2F2 in the negative regulation of Survivin expression. In addition, we identify a novel E2F-binding site in the survivin promoter and show that mutation of either the p53- or E2F-binding sites is sufficient to increase promoter activity. These studies suggest that compromise of either p53 or Rb pathways during melanocyte transformation leads to upregulation of Survivin expression in melanoma.

Keywords: Survivin, melanocyte, p53, Rb, E2F


Melanoma, a malignant tumor arising from melanocytes, is generally associated with poor response to conventional chemotherapy and radiation (1). Inherent resistance to apoptosis is largely responsible for treatment failure in melanoma, and there is considerable interest in developing apoptosis-based therapeutics to improve responses in patients with advanced disease (2). Among the many acquired genetic changes in melanoma, the best characterized involve: 1) activating mutations in BRAF, HRAS or NRAS (3); 2) increased activity of telomerase (4); 3) defects in retinoblastoma (Rb) signaling (5); and 4) compromised p53 signaling (68). Two recent studies have shown that introduction of these four genetic events into normal human melanocytes is completely sufficient for transformation into invasive melanocytic lesions (9, 10). It is therefore likely that apoptotic dysregulation in melanoma stems from one or more of these transforming events.

Among the many apoptotic regulators expressed in human melanoma, the inhibitor of apoptosis (IAP) protein and mitotic regulator Survivin (11, 12) is notable for its low expression in normal melanocytes (13). Its importance in melanoma development and as a potential therapeutic target in this disease is indicated by several recent animal studies from our group (14, 15). Furthermore, Survivin expression has been associated with reduced survival in patients with advanced melanoma (16, 17).

Although the mechanism(s) responsible for Survivin upregulation during melanocytic transformation have not been reported, epigenetic, genetic and post-translational mechanisms for survivin gene regulation have been described in other cell types. The survivin promoter was found to be methylated in ovarian cancers and unmethylated in normal ovarian tissues (18), although such differences in promoter methylation were not found in earlier comparisons of normal and malignant tissues (19). Although survivin mutations have not been described in cancer, a promoter mutation (C−31 → CG) was reported in various carcinoma cell lines (20). Upregulation of Survivin in tumor cells may also result from increased half-life of the Survivin protein, which is regulated by ubiquitination (21) and may be stabilized through interactions with other binding partners (22). Multiple factors have been shown to effect Survivin transcription in malignant cells. Survivin is transcriptionally upregulated by Dec1 (23), Sp1 (19), c-myc (24) and KLF5 (25), all of which show aberrant activation in tumors as compared to normal tissues. Various transcription factors including Stat3 (26), HIF-1 α (27), and Rb-E2F1 (28) have been shown to interact directly with the survivin promoter in breast cancer and lung cancer cell lines. While p53 was shown to repress survivin transcription by direct binding to the survivin promoter in a lung adenocarcinoma line (29), another study in an ovarian carcinoma cell line found that negative regulation of Survivin by p53 was not affected by mutation or deletion of the putative p53-binding site in the survivin promoter (30). Most of the work on survivin gene regulation has been in malignant cells, and little is known regarding mechanisms of survivin repression in normal cells.

Here, we investigate the regulation of Survivin expression in normal melanocytes by examining upstream factors involved in melanocyte transformation, and show that both p53 and Rb are required for Survivin repression in this cell type. We show that E2F2, acting downstream of Rb, plays a novel role in the negative regulation of survivin. We identify a novel functional E2F-binding site in the survivin promoter, and show that mutation of either the p53- or E2F-binding site increases survivin transcription. Thus our data suggests that upregulation of Survivin expression in melanoma likely results from compromise of either p53 or Rb pathways.


Oncogenic transformation of human melanocytes results in upregulation of Survivin

Consistent with previous reports (13, 31), expression of Survivin is low in normal human melanocytes compared to melanoma cells (Figure 1a). In order to determine the specific oncogenic event that causes upregulation of Survivin in melanoma, we used a previously described model system (10) in which introduction of hTERT and disruption of p53 and Rb activity (by introduction of the Simian Virus 40 early region [SV40ER]) was sufficient to immortalize normal human melanocytes, and further addition of activated HRas (RasG12V) or constitutively active c-Met receptor (TPR-Met) resulted in tumorigenicity in vivo. We used a retroviral system to stably introduce SV40ER into human melanocytes, and then examined Survivin expression in this cell line (Mel-SV40ER), in normal melanocytes, in a panel of immortalized and transformed melanocytes (10) and three human metastatic melanoma lines. We found that Survivin expression in Mel-SV40ER was greatly increased over that in normal melanocytes, with levels approaching those seen in melanoma cell lines (Figure 1a). By comparison to Mel-SV40ER, there was some enhancement of Survivin expression in cells transduced with SV40ER, HRasG12V and hTERT, but not in cells transduced with SV40ER and either hTERT or hTERT plus TPR-Met (Figure 1a). Thus the upregulation of Survivin in these melanocyte lines compared to normal melanocytes was primarily attributable to SV40ER. We concluded that the oncogenic events leading to upregulation of Survivin during melanocytic transformation must be downstream of SV40ER.

Figure 1
Survivin expression is negatively regulated by p53 and Rb in human melanocytes. (a) Cell lysates were obtained from normal human melanocytes (Mel), human melanocyte lines infected with retrovirus expressing SV40ER (Mel-SV40ER); SV40ER and hTERT (Mel-STV); ...

Knockdown of p53 or Rb in melanocytes causes transcriptional upregulation of Survivin

The SV40ER encodes the large T antigen, which contributes to cellular transformation through inhibition of p53 and Rb (32). Earlier studies (9) showed that knockdown of p53 (with dominant-negative p53) and Rb (with dominant active CDK4) in conjunction with hTERT and activated NRas were sufficient to transform human melanocytes, which suggested that p53 and Rb were the mediators downstream of SV40ER that caused upregulation of Survivin expression. In order to test this, we transiently transfected siRNAs against p53 or Rb into normal human melanocytes, and examined Survivin levels by Western blotting over a 24–72 h period. Substantial knockdown of p53, which was evident by 24 h and sustained for 72 h, was associated with increased Survivin expression as early as 24 h following transfection (Figure 1b). Similarly, Rb knockdown, which increased over 24–72 h following siRNA transfection, was associated with robust induction of Survivin expression (Figure 1b). Thus knockdown of either p53 or Rb was sufficient for induction of Survivin expression in normal melanocytes, suggesting that inactivation of either p53 or Rb may be the crucial event upregulating Survivin expression during melanocyte transformation.

To determine whether p53 and Rb affected Survivin mRNA levels, we targeted p53 and Rb using RNAi and looked for changes in Survivin mRNA levels at 24 h by semi-quantitative RT-PCR. As shown in Figure 1c, there was a significant increase in Survivin mRNA levels following knockdown of either p53 or Rb, indicating that these factors regulate Survivin expression transcriptionally. Cycloheximide chase assays indicated that the half-life of Survivin protein (2–4 hrs) is unchanged after knockdown of either p53 or Rb (Supplementary Figure 1). These data suggest that both p53 and Rb repress survivin by transcriptional mechanisms, and do not affect survivin protein stability.

Absence of epigenetic regulation of Survivin in melanocytes

Given the previous report of methylation-dependent repression of Survivin in normal ovarian tissue (18), we examined whether methylation was involved in regulation of Survivin expression in normal melanocytes and melanoma cells. There are a total of 15 restriction sites for the methylation-sensitive enzymes HpaII and HhaI within the 250-bp canonical CpG island and upstream sequences of the survivin promoter, and the early exonic region (Figure 2a). Genomic DNA isolated from normal melanocytes and two melanoma cell lines was treated with HpaII or HhaI, and then subjected to PCR using primers flanking overlapping segments of this region (−650 to +555, Figure 2a). In both melanocytes and melanoma cells, enzymatic digestion disrupted PCR amplification of survivin but not actin sequences (Figure 2b), suggesting that the survivin promoter and early exonic region is unmethylated in these cells. To confirm lack of survivin promoter methylation, melanocytes were grown in the absence or presence of the demethylating agent 5-aza-2′-deoxycytidine (5-aza), and then examined for Survivin expression. While treatment with 5-aza induced expression of the maspin gene, previously shown to be repressed by methylation in melanocytes (33), there was no corresponding upregulation of Survivin expression (Figure 2c). These data suggest that the survivin promoter is unmethylated in normal melanocytes, and that repression of Survivin expression is not due to promoter methylation.

Figure 2
Methylation-independent regulation of Survivin. (a) Schematic depicting survivin promoter and proximal exonic sequence, and location of HpaII (open circles) and HhaI (filled circles) sites, and binding sites for p53 (open box) and E2F factors (shaded ...

Cell cycle-dependent regulation of Survivin

Survivin plays a role in mitosis (12), and has been shown to be upregulated in G2/M in malignant cell lines (34), although its expression in developing tumors in vivo may be cell cycle-independent (35). In order to examine cell cycle-specific changes in Survivin expression in normal melanocytes, we enriched for cells at different phases of the cell cycle using specific chemical inhibitors. Melanocytes were treated with mimosine, thymidine, or nocodazole to arrest cells in the G1, S or G2/M phases, respectively (Figure 3a). Western blotting showed that Survivin expression was relatively decreased during G1, but increased during the S and G2/M phases (Figure 3b). To determine whether Rb and p53 activity correlated with the cell cycle-dependant variation in Survivin expression, we assessed activity of p53 and Rb at various stages of the cell cycle. As Rb is inactivated by phosphorylation, its activity correlates inversely with levels of its phosphorylated forms (36). A direct transcriptional target of p53 is p21, whose protein levels reflect p53 activity (37). The phosphorylated forms of Rb (indicating Rb inactivation) were increased during S and G2/M and diminished during G1, though significantly, total Rb levels still remained high during G1. Levels of p21 (indicating active p53) were high during G1 and G2/M, but virtually undetectable during S phase (Figure 3b). Thus increased activity of p53 and Rb during G1 is associated with decreased Survivin expression, whereas decreased p53 and Rb activity during S phase correlate with higher Survivin levels. These data are consistent with our earlier experiments in which Survivin was upregulated in cells with either Rb or p53 knockdown (Figure 1b). However, during G2/M, increased Survivin levels correspond to inactivation of Rb, even though p53 activity (as indicated by p21 levels) continues to be high. This suggests that in normal melanocytes, Rb inactivation can upregulate Survivin even in the presence of elevated amounts of active p53.

Figure 3
Cell cycle analysis of Survivin expression and activity of p53 and Rb. (a) Melanocytes (Mel) were untreated (control) or treated with mimosine, thymidine, or nocodazole to arrest cells in the G1, S, and G2M phases, respectively. After 24 h, cells were ...

Interaction of p53 and Rb pathways in the regulation of Survivin

As we were unable to knock out p53 and Rb simultaneously using transient transfection (due to significant cellular toxicity), we used a lentiviral system to deliver siRNAs stably into human melanocytes, allowing for more efficient knockdown of p53 and Rb singly or in combination. We found that the negative regulatory effects of p53 and Rb on Survivin expression were not additive, as knockdown of p53 or Rb singly or in combination all resulted in similar increased levels of Survivin (Figure 4a). Knockdown of p53 was associated with downregulation of p21, but did not significantly alter total or phosphorylated Rb levels (Figure 4a). On the other hand, knockdown of Rb was associated with a corresponding decrease in the phosphorylated forms of Rb, but no change in p53 or p21 expression levels (Figure 4a). These data suggest that p53 and Rb do not influence each other’s basal activity in normal melanocytes but rather act independently to repress Survivin expression, and that basal activity of both p53 and Rb is simultaneously required for Survivin repression in this cell type.

Figure 4
Lack of interaction of p53 and Rb pathways in Survivin regulation. (a) Melanocytes were infected with lentiviruses expressing control scrambled siRNA (Scr), p53 siRNA, Rb siRNA, or a combination of both p53 and Rb siRNA-expressing lentiviruses. After ...

As noted above, p21 is a direct transcriptional target of p53, and is responsible for the regulation of several p53 target genes. While p21 exerts its effects primarily by influencing Rb activity, it may also independently affect other cellular signaling pathways (38). To determine whether p53 exerts its negative effects on Survivin expression via p21, we examined Survivin levels following transfection of melanocytes with siRNA against p21. Partial knockdown of p21 was associated with modest upregulation of Survivin (Figure 4b), suggesting that at least part of the effect of p53 on Survivin expression may be mediated through p21.

Binding of p53 and E2F factors to the survivin promoter

We next investigated direct binding of p53 to the canonical p53-binding site in the proximal survivin promoter (Figure 2a) by electrophoretic mobility shift assay (EMSA). Since the DNA binding activity of p53 requires a conformational change induced by specific antibody binding (39), EMSAs were performed in the presence of the activating anti-p53 antibody Pab421. We constructed a radio-labeled probe corresponding to the putative p53-binding site and flanking sequences in the survivin promoter, which formed super-shifting complexes when combined with melanocyte nuclear extracts (Figure 5a). These complexes were disrupted by 100-fold excess of cold probe but not similar excess of non-specific probe (Figure 5a).

Figure 5
Binding of p53 and E2F factors negatively regulates the survivin promoter. (a) Melanocyte nuclear extracts were incubated with 32P-labeled duplexes corresponding to the consensus binding site for p53 in the survivin promoter and anti-p53 antibody pAb ...

Since the transcriptional effects of Rb are mediated through modulation of the activity of E2F factors (36), we examined the survivin promoter for potential E2F-binding sites, and identified a novel E2F-binding site 120 bp upstream of the p53-binding site in the survivin promoter. In order to test its functionality, we prepared radio-labeled probes corresponding to this site and flanking sequences, incubated them with melanocyte nuclear extracts, and observed complexes that could be competed away with 100-fold excess unlabeled wild-type probe but not with similar excess of mutant probe (Figure 5b). Taken together these data suggest that both p53 and Rb (via particular E2F factors) may modulate Survivin expression through direct interactions with the promoter in melanocytes.

We further investigated the importance of these particular E2F- and p53-binding sites in the regulation of Survivin expression by transient reporter assay using YUSAC2 and YUGEN8 cells. Cells were transfected with a construct consisting of 1.4 kb survivin promoter sequence driving luciferase expression, or similar constructs containing discreet mutations in the p53 and/or E2F sites. In YUSAC2 cells, we found a significant increase in survivin promoter activity upon mutation of either site, suggesting that both sites are repressive for Survivin transcription (Figure 5c). When both sites were mutated in the same construct, a similar increase in activity was seen and an additive effect on promoter activity was not observed (Figure 5c). Similar results were obtained in YUGEN8 cells (Figure 5d). These data confirm the importance of both the p53 and E2F sites in repressing Survivin expression, and are consistent with our findings above that both p53 and Rb are required for repression of Survivin in normal melanocytes.

E2F2 is a negative regulator of Survivin expression

Finally, we screened melanocytes and YUSAC2 cells for expression of particular E2F factors that may be acting downstream of Rb and controlling Survivin expression. While E2F2 and E2F4 were expressed in both cell types (Figure 6a), other E2F factors, namely E2F1 and E2F3, were not expressed in either cell type at detectable levels (not shown). Our data (Figure 5c,d) suggest that one or more of the E2F factors binding to the survivin promoter play a negative role in transcription. E2F2 has been previously characterized as positive regulator of gene transcription (40). However, since it has also been shown to act as a negative regulator of cellular proliferation in certain contexts (41), we investigated the possibility that E2F2 may negatively regulate Survivin expression in normal melanocytes. Using RNAi we achieved significant knockdown of E2F2, which was associated with upregulation of Survivin expression (Figure 6b). Similar results were obtained following E2F2 knockdown in HeLa cells (Figure 6c). Thus E2F2 is an important negative regulator of Survivin acting downstream of Rb.

Figure 6
E2F2 is a negative regulator of Survivin. (a) Lysates from human melanocytes and YUSAC2 melanoma cells were blotted for E2F2, E2F4 and Actin as indicated. (b) Melanocytes were transfected with 20 nM scrambled siRNA (Scr) or siRNA targeting E2F2. Cell ...


Our previous studies in melanoma cell lines (31, 42) and animal models (14, 42) have implicated Survivin as an important molecule in melanoma pathogenesis. Its clinical relevance in this disease is underscored by studies demonstrating a correlation between Survivin expression and poor outcome in patients (16, 17). To better understand the role of Survivin in human melanoma and to design optimal therapies targeting Survivin, it will be important to elucidate the mechanism(s) of Survivin upregulation during melanocyte transformation, as well as mechanism(s) of repression of Survivin expression in normal melanocytes. Thus our approach taken here was to examine upstream factors known to be involved in melanocyte transformation (9, 10), and we found that p53 and Rb independently repress Survivin expression in normal melanocytes.

Our results suggest that compromise of either p53 or Rb pathways in melanoma would be sufficient for upregulation of Survivin expression. Genetic alterations are common in human melanoma, and usually involve mutational inactivation or deletion of tumor suppressors or mutational activation or amplification of oncogenes leading to aberrant signaling (43). Interruption of the p16INK4A-CDK4-Retinoblastoma (Rb) pathway, due to germ-line mutations in p16 or CDK4 (8) or p16 mutations in sporadic melanomas (44), promotes cell cycle progression through hyper-phosphorylation of Rb and consequent activation of E2F transcription factors (36). The p14ARF-HDM2-p53 pathway promotes p53-dependent apoptosis, and may be disrupted by germ-line mutations (8) or deletions (7) in p14 that lead to increased HDM2-mediated degradation of p53, or acquisition of inactivating p53 mutations (6).

The role of p53 in tumor suppression has been well characterized, acting in a gene-specific manner as either transcriptional activator (for pro-apoptotic genes such as bax) or repressor (for various oncogenes such as c-myc) (45). Induction of wild type p53 by DNA-damaging agents such as UV or doxorubicin (29), or introduction of exogenous p53 (30), have been shown to downregulate Survivin expression in malignant cells. However, the role of p53 in the regulation of Survivin under basal conditions in normal cells has yet to be defined. We found that endogenous p53, in the absence of DNA-damaging agents or other stimuli known to activate p53, plays a critical role in the repression of Survivin expression in normal human melanocytes.

Earlier studies have suggested that p53 does not bind to the survivin promoter (30, 46). In both these studies, performed in malignant cell lines, mutational analysis of the survivin promoter suggested that the p53-binding site was nonfunctional, and that p53 acted through other mechanisms to repress Survivin. By contrast, we found in normal melanocytes that the p53-binding site is functional as evidenced by direct binding of p53 to the survivin promoter and increased promoter activity upon mutation of the p53-binding site. While it has been suggested that p53 exerts its effects on Survivin via the p21-Rb-E2F pathway (46), our data in melanocytes suggests that the effect of p53 on Survivin is at least partially independent of p21. In addition, we show that siRNA-mediated silencing of p53 in melanocytes has no apparent effect on Rb activity, suggesting that in melanocytes p53 exerts its actions on Survivin expression directly. The discrepant findings regarding p53-binding to the survivin promoter may be due to the fact that malignant cells often exhibit a variety of defects upstream and downstream of p53 which may compromise p53 function (such as DNA binding) even in the absence of p53 mutation (45).

As the effects of Rb are mediated through multiple E2F transcription factors, repression of individual genes by Rb depends on the nature of particular Rb-E2F interactions and the activity of the Rb-bound proteins recruited to the promoter (36). It has been suggested that E2F factors bind adjacent to the p53-binding site in the survivin promoter (29, 47). We have, however, identified a novel E2F-binding site 120 bp upstream of the p53-binding site, and shown using reporter assays that this site plays a repressive role in survivin transcription. Earlier studies reported that Rb represses Survivin expression by binding to and inactivating E2F3 in mouse fibroblasts (47) or E2F1 in lung carcinoma cells (28). By contrast, we could not detect expression of E2F1 and E2F3 in human melanocytes, while E2F2 was highly expressed in this cell type. Although previous studies implicated E2F2 as a positive transcriptional regulator (40), our finding that E2F2 knockdown led to Survivin upregulation identifies it as a novel negative regulator of Survivin expression. Thus the mechanism of E2F-mediated regulation of Survivin expression may be tissue-specific, and differ between melanocytes and other cell types.

While the p53 gene is commonly mutated in other cancers, melanomas generally exhibit far lower rates of p53 mutation (6), although p53 may be compromised in melanoma by deletions in p14ARF (7). Nevertheless, the high levels of p53 seen in some melanoma tumors (48) may at first appear paradoxical given that they consistently express high levels of Survivin as we have observed previously (13). Our data may resolve this paradox in that p53 and Rb are both required to repress Survivin expression in melanocytes, as inactivation of either factor is sufficient to derepress Survivin expression. Furthermore, we did not observe any additive effect of knocking down p53 and Rb by RNAi or mutating both the p53- and E2F-binding sites in the promoter. These findings suggest that p53 and Rb are both required to repress Survivin expression. Consistent with this notion, Rb inactivation (by phosphorylation) in G2/M was sufficient to upregulate Survivin expression, even in the presence of high amounts of activated p53. In melanoma, the near-ubiquitous defects in Rb signaling (due to inactivation of p16, mutation of CDK4, or over-expression of cyclin D1) (36) would be predicted to upregulate Survivin expression even in the context of wild-type p53.

The secondary events leading to repression of the survivin promoter, following p53 and Rb (via E2F factors) binding, have not been clearly defined. It has been suggested that p53 recruits DNMT1 causing methylation of the survivin promoter and transcriptional repression (49). We found, somewhat surprisingly given earlier studies (18), that the survivin promoter is unmethylated in normal melanocytes, suggesting that the mechanism of p53 repression of survivin may be tissue-specific. Several transcription factors, including Dec1 (23), Sp1 (19), KLF5 (25) and c-myc (24) have been shown to facilitate trans-activation by binding to the proximal part of the survivin promoter – interestingly in the same region where we have demonstrated p53- and E2F2-binding in this study. It is possible that p53 and Rb physically displace these transcriptional activators from the survivin promoter. Alternatively, given that histone deacetylases may be recruited to target promoters by p53 and Rb, these factors may promote repressive modifications of chromatin and thereby block trans-activation. Possible interactions between p53 and Rb on the survivin promoter, histone modifications secondary to p53 and Rb binding, and recruitment of other repressive factors by p53 and Rb may underlie tissue-specific differences in the regulation of Survivin expression, and merit further study.

Materials and methods


Normal human melanocytes were prepared from discarded foreskins, as approved by the Institutional Review Board at the University of Utah (#8476). Melanocytes were isolated and propagated as described previously (13), and experiments were performed with cells that had been passaged 2–4 times. The Mel-SV40ER line was generated by infection of melanocytes with an SV40ER-expressing retrovirus kindly provided by Stephen Lessnick (Huntsman Cancer Institute, Salt Lake City, UT) in the presence of polybrene (8 μg/ml, Sigma), followed by selection with zeocin (0.5 mg/ml, Invitrogen) as described (50). Transformed melanocyte lines Mel-STV, Mel-STR, and Mel-STM (10) were generously provided by Robert Weinberg (Whitehead Institute, Cambridge, MA). These transformed melanocyte lines, and melanoma cell lines YUGEN8 and LOX (31), were all maintained in Dulbecco’s Minimal Essential Media containing 5% heat-inactivated fetal bovine serum and antibiotics.

Western blotting and cycloheximide chase assays

Melanocytes were grown in normal melanocyte medium, or medium containing 50 μg/mL cycloheximide (Sigma) or various cell-cycle inhibitors (described below). After washing with PBS, cells were scraped into lysis solution containing 2% SDS, 50 mM Tris (pH 7.4), and protease (P-2714) and phosphatase (P-2850) inhibitor cocktails (both from Sigma). The lysate was heated at 94 °C for 5 min, protein quantitated using the BCA protein assay reagent (Pierce, Rockford, IL), and thereafter stored at −20 °C. Lysates (20–50 μg) were electrophoresed on denaturing SDS-PAGE gels, and then transferred to PVDF membranes (Millipore, Billerica, MA). After blocking in PBS containing 5% non-fat dry milk and 0.1% Tween, membranes were incubated with primary antibodies against Survivin (1μg/ml) (31), β-actin (100 ng/ml) (A-3853, Sigma), p53 (100 ng/ml) (OP43, EMD Biosciences, San Diego, CA), p21 (100 ng/ml) (OP64, EMD Biosciences), Rb (200 ng/ml) (sc-50, Santa Cruz Biotechnology (Santa Cruz, CA), Rb phosphorylated at residues 780, 795 and 807/811 (100 ng/ml) (9307, 9301 and 9308 respectively, Cell Signaling Technology, Danvers, MA), E2F1, E2F2, E2F3 or E2F4 (200 ng/ml) (sc-193X, sc-633X, sc-878X and sc-866X respectively, Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h at room temperature. After staining with species-appropriate secondary horseradish peroxidase-conjugated antibodies (Perkin-Elmer Life Sciences, Boston, MA), bands were visualized by enhanced chemiluminescence (Perkin-Elmer Life Sciences) and autoradiography.


Oligonucleotide pairs targeting human p53 (5′-GACUCCAGUGGUAAUCUACdTdT-3′ and 5′-GUAGAUUACCACUGGAGUCUUdTdT-3′), Rb (5′-AAGUUUCAUCUGUGGAUGGAGdTdT-3′ and 5′-CUCCAUCCACAGAUGAAACUUdTdT-3′, 5′-AAUGGUUCACCUCGAACACCCdTdT-3′ and 5′-GGGUGUUCGAGGUGAACCAUUdTdT-3′), E2F2 (5′-GACUCGGUAUGACACUUCGdTdT-3′ and 5′-CGAAGUGUCAUACCGAGUCdTdT-3′), or a control scrambled sequence (5′-AGACAGAAGACAGAUAGGCdTdT-3′ and 5′-GCCUAUCUGUCUUCUGUCUdTdT-3′) were synthesized and solubilized in RNAi solubilization buffer (Qiagen, Valencia, CA), mixed to give a stock concentration of 20 μM, heated at 90 °C for 1 min followed by annealing at 37 °C for 1 h, and then aliquotted and stored at −20 °C. Oligonucleotides targeting p21 (sc-29427) were obtained from Santa Cruz Biotechnology. Transfections were performed in 6-well plates. The RNAi duplexes targeting p53 or E2F2 (20 nM for melanocytes, 50 nM for Hela, final comcentration), Rb (two duplexes used in combination at 50 nM final concentration of each), or p21 (100 nM final concentration) were mixed with 2 μL Lipofectamine-2000 (Invitrogen) and 100 μL Opti-MEM (Invitrogen) for each well, and after 25 min added drop-wise to melanocytes (80% confluent in normal melanocyte media as described above, but without antibiotics). After 24 h, the media was replaced with normal melanocyte media containing antibiotics.

Lentiviral vectors expressing control scrambled siRNA, or siRNA targeting human p53 or Rb, and packaging constructs pRSV-REV, pMDLg/pRRE, and pHCMV-G were generously provided by Maria Soengas (University of Michigan) and are described elsewhere (51, 52). For virus production, 293 FT cells (American Type Culture Collection, Manassas, VA) were grown in 0.5 mg/ml G418 (Invitrogen) to 80% confluence in a 100-mm dish. Approximately 4 μg of each plasmid were added to 0.5 mL of a 250 mM CaCl2 solution, which was then added drop-wise (while blowing air bubbles) to an equal volume of 2X HEPES-buffered saline and left to stand for 45 min to allow formation of a fine precipitate. This mixture was then added drop-wise to the cells in 9 ml media containing 25 μM chloroquine (Sigma). The media was replaced 24 h later to remove the transfection mixture and the chloroquine, and live virus collected at 48–72 h. The virus was filter-sterilized (0.45 μm BioExpress syringe filter, Intermountain Scientific Corp., Kaysville, UT), aliquotted, and stored at −80 °C. For lentiviral infection, undiluted lentivirus along with polybrene (8 μg/mL, Sigma) was added to melanocytes (80% confluent) and after 4–6 h, virus-containing medium was aspirated and replaced with normal melanocyte media.


RNA was harvested from cells using TriReagent (Molecular Research Center, Cincinnati, OH) as per the manufacturer’s instructions. Approximately 0.5 μg total RNA was reverse-transcribed using SuperScript II Reverse Transcriptase (Invitrogen), and equal amounts of cDNA (1 μL of each 20 μL reaction) were subjected to PCR using primers for survivin (5′-GTTGCGCTTTCCTTTCTGTC-3′ and 5′-AGGGAATAAACCCTGGAAGTG-3′) or β-actin (5′-CTCCTGCTTGCTGATCCACAT -3′ and 5′-AACCGCGAGAAGATGACCCAG-3′) for 30 cycles (94 °C for 30 sec, 58 °C for 30 sec, and 72 °C for 1 min). The products were visualized in ethidium bromide-containing 1.5 % agarose gels.

Methylation assays

Genomic DNA was prepared from melanocytes and melanoma cells using a DNAeasy kit (Qiagen) according to the manufacturer’s instructions. Restriction digests were carried out with 0.2 μg DNA in 20 μL with 10 units of either HpaII (Invitrogen) or HhaI (Fermentas, Hanover, MD) for 4 h at 37 °C, then 2 ng DNA was subjected to PCR using JumpStart Taq ReadyMix (Sigma) and primer sets designed to amplify regions of the survivin −650/+130 (5′-CCTGGAAACCCAGGTCGTGC-3′, 5′-GAGATGCGGTGGTCCTTGAG-3′), survivin −216/+555 (5′-AGTGATGCTCCTGCCTGCCTAG-3′, 5′-AGAAGACTTACATGGGGTCGT-3′), and β-actin (5′-CTCCTGCTTGCTGATCCACAT-3′, 5′-AACCGCGAGAAGATGACCCAG-3′) genes. After incubation at 95 °C for 3 min, 40 cycles were performed (95 °C for 30 sec, 60 °C for 30 sec, 72 °C for 1 min), followed by extension at 72 °C for 1 min, and products were visualized in 1% agarose gels containing ethidium bromide. In separate experiments, melanocytes were plated at 20–30% confluency in the absence or presence of 0.5 μM 5-aza (Sigma), which was re-added each day. After 96 h, cell lysates were analyzed by Western blotting using antibodies against Survivin, β-Actin, and Maspin (clone G167–70, BD Biosciences, San Jose, CA).

Cell cycle analysis

Melanocytes were grown to 80% confluency in a 12-well plate and treated with each of the following cell cycle inhibitors (all from Sigma): 400 μM mimosine for G1 arrest, 2 mM thymidine for S-phase arrest, and 40 ng/ml nocodazole for G2/M arrest. Cells were harvested by trypsinization 24 h later, washed with cold PBS (without Ca++ or Mg++), resuspended in 500 μL cold PBS, and tubes were placed on ice. Ethanol (450 μL) was added, and after gentle mixing, the cells were stored overnight at 4°C. After washing in PBS, cells were resuspended in 250 μL staining solution consisting of 50 μg/mL propidium iodide (Sigma), 0.1% Triton X-100, and 100 μg/mL RNAse A in PBS. After incubation in the dark at room temperature for 30–60 min, cells were analyzed on a FACSort using CellQuest software (BD Biosciences, Franklin Lakes, NJ).


For preparation of nuclear extracts, cells were grown to 80% confluence in a 6-well plate, washed twice with cold PBS, scraped into 0.5 ml cold PBS, and microfuged at 350 g for 5 min. Cells were washed with 0.5 mL Buffer A (10 mM HEPES pH 7.8, 15 mM KCl, 2 mM MgCl2, 0.1 mM EDTA with freshly added 1 mM DTT, 1mM PMSF, and protease and phosphatase inhibitor cocktail [Sigma]) and then resuspended in 0.2 ml Buffer A. After holding on ice for 10 minutes, NP-40 was added to a final concentration of 0.5% and the tube was microfuged at 1330 g for 15 min. The supernatant was discarded and the nuclear pellet was resuspended in 30 μL of Buffer B (20 mM HEPES pH 7.8, 1.5 mM MgCl2, 420 mM NaCl, 0.2 mM EDTA, and 25% glycerol with freshly added 0.5 mM DTT, 0.5 mM PMSF and protease and phosphatase inhibitor cocktails), nutated at 4 °C for 15 min, and then microfuged at 16,300 g for 10 min. The supernatant was transferred to a new tube and 50 μL Buffer C (20 mM HEPES pH 7.8, 50 mM KCl, 0.2 mM EDTA with freshly added 0.5 mM DTT, 0.5 mM PMSF and protease and phosphatase inhibitor cocktails) was added, to bring the total volume of nuclear extract to 80 μL. The nuclear extract was aliquotted and stored at −80 °C.

To perform EMSAs, the following complementary pairs of HPLC-purified oligos were obtained from the University of Utah DNA/Peptide Core Facility (mutant nucleotides in lower case): survivin promoter containing the p53-binding site (5′-GCCTAAGAGGGCGTGCGCTCCCGACATGCCCCGCGG-3′ and 5′-CCGCGGGGCATGTCGGGAGCGCACGCCCTCTTAGGC-3′), and the wild-type (5′-CAGGGACGAGCTGGCGCGGCGTCGCTGGGT-3′and 5′-ACCCAGCGACGCCGCGCCAGCTCGTCCCTG-3′) and mutated (5′-CAGGGACGAtaTGGataGattTCGCTGGGT-3′ and 5′-ACCCAGCGAaatCtatCCAtaTCGTCCCTG-3′) E2F site. The oligos were then labeled with γ32P-ATP (MP Biomedicals, Solon, OH), annealed and stored at a concentration of 100 nM at −20 °C. For the binding reaction, 5 μL of nuclear extract was thawed on ice and added to labeled oligo duplex that had been diluted down to about 1×104 cpm in 1X binding buffer (40 mM HEPES pH 7.8, 10 mM MgCl2,50 mM KCl, 0.05 mM EDTA, 20%glycerol, with freshly added 5 mM DTT, 1 mg/ml BSA and 0.1 mg/ml Poly dIdC). For competition reactions, 100-fold excess of oligo duplex were diluted similarly in 1X binding buffer and added to the reaction, which was brought up to a total volume of 20 μL in 1X binding buffer. Unlabeled duplexes (5′-CAGGGACGATATGGATAGATTTCGCTGGGT-3′ and 5′-ACCCAGCGAAATCTATCCATATCGTCCCTG-3′; 5′-CGCCATTAACCTAACTATTTGAATCG-3′ and 5′-CGATTCAAATAGTTAGGTTAATGGCG-3′) were used as non-specific competitors for p53-binding experiments. The reaction was allowed to stand at room temperature for 20 min. For super-shift experiments, 2 μg antibody specific for p53 (pAb 421, EMD Biosciences) or individual E2F factors (E2F1, sc-193X; E2F2, sc-633X; E2F3, sc-878X; E2F4, sc-866X; Santa Cruz Biotechnology) was also added. Each sample (18 μL) was run on a 4% non-denaturing polyacrylamide gel that had been pre-run for 1 h at 4 °C. The gel was then subjected to vacuum drying at 80 °C using a large gel dryer, exposed in a Phosphor Cassette (Molecular Dynamics, Sunnyvale, CA) and bands were visualized using a Storm PhosphorImager (Molecular Dynamics).

Transfection reporter assays

The construct pLuc1430c contains the proximal 1.4 kb of the human survivin promoter upstream of the Firefly-luciferase reporter, and has been previously described (19). Individual mutant promoter constructs were generated by PCR-based segment overlap extension using this construct as a template. For the p53-binding site mutant, separate products were generated using each of the following primer sets (mutant nucleotides in lower case): 5′-CGGGAGCatttaCCCTCTTAGGCG-3′, 5′-AGTGGATCCCCCAAATTGACA-3′; and 5′-GCGGGCCTCTTCGCTATTAC-3′, 5′-GGACCGCCTAAGAGGGtaaatGCTCCCGACAT. These products were annealed and used in a second PCR reaction with the primers 5′-CCAGCTCCCTTGTCTTCTTATC-3′ and 5′-GCGGGCCTCTTCGCTATTAC-3′ to generate the final product, which was digested with HindIII and MluI and cloned into these sites of the wild-type construct. For the E2F-binding site mutant, the following primer sets were used: 5′-GCGGGCCTCTTCGCTATTAC-3′, 5′-GCACCCAGCGAaatCtatCCAtaTCGTCCCTGCCC-3′; and 5′-GATAAGCTTGATATCGAATTCCTGCAGCC-3′, 5′-GGGCAGGGACGAtaTGGataGattTCGCTGGGTGC-3′. These products were annealed and used in a second PCR reaction with the primers 5′-CCAGCTCCCTTGTCTTCTTATC-3′ and 5′-GATAAGCTTGATATCGAATTCCTGCAGCC-3′ to generate the final product, which was digested with HindIII and MluI and cloned into these sites of the wild-type construct. To generate the double p53/E2F mutant, the p53 mutant construct was used as an initial template rather than wild-type construct. Specific mutations, as well as lack of spontaneous mutations, were confirmed by DNA sequencing.

Cells were plated in 12-well plates, and transfected with 200 ng of Firefly construct and 20 ng of pRL-TK, encoding the Renilla-luciferase reporter upstream of the TK promoter (53), using Lipofectamine-2000 as above. After 24 h, the cells were harvested and reporter assays performed using the Dual Luciferase Reporter Assay System (Promega, Madison, WI) according to the manufacturer’s instructions. The lysates were pipetted into a microtiter plate (#2010, Dynex Technologies, Chantilly, VA) and luminescence was measured using the MLX Microplate Luminometer (Dynex Technologies). Readouts of Firefly luminescence were normalized to Renilla luciferase activity (internal control) and expressed as arbitrary units.

Supplementary Material


We thank Robert Weinberg for transformed melanocyte lines Mel-STV, Mel-STR and Mel-STM, Stephen Lessnick for the SV40ER-expressing retrovirus, Maria Soengas for the p53 and Rb RNAi lentiviruses, Sancy Leachman for helpful discussions, and Ed Levine and Murray Cotter for reviewing the manuscript. This work was supported by NIH grant AR050102 and the Huntsman Cancer Foundation.


1. Miller AJ, Mihm MC., Jr Melanoma. N Engl J Med. 2006;355:51–65. [PubMed]
2. Satyamoorthy K, Bogenrieder T, Herlyn M. No longer a molecular black box--new clues to apoptosis and drug resistance in melanoma. Trends Mol Med. 2001;7:191–194. [PubMed]
3. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003;9:6483–6488. [PubMed]
4. Pirker C, Holzmann K, Spiegl-Kreinecker S, Elbling L, Thallinger C, Pehamberger H, Micksche M, Berger W. Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes. Melanoma Res. 2003;13:483–492. [PubMed]
5. Sharpless E, Chin L. The INK4a/ARF locus and melanoma. Oncogene. 2003;22:3092–3098. [PubMed]
6. Albino AP, Vidal MJ, McNutt NS, Shea CR, Prieto VG, Nanus DM, Palmer JM, Hayward NK. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res. 1994;4:35–45. [PubMed]
7. Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, Sibley K, Whitaker L, Knowles M, Bishop JN, Bishop DT. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet. 2001;10:55–62. [PubMed]
8. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006;66:9818–9828. [PubMed]
9. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet. 2005;37:745–749. [PMC free article] [PubMed]
10. Gupta PB, Kuperwasser C, Brunet JP, Ramaswamy S, Kuo WL, Gray JW, Naber SP, Weinberg RA. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet. 2005;37:1047–1054. [PMC free article] [PubMed]
11. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581–8589. [PubMed]
12. Vong QP, Cao K, Li HY, Iglesias PA, Zheng Y. Chromosome alignment and segregation regulated by ubiquitination of survivin. Science. 2005;310:1499–1504. [PubMed]
13. Bowen AR, Hanks AN, Allen SM, Alexander A, Diedrich MJ, Grossman D. Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol. 2003;120:48–55. [PubMed]
14. Yan H, Thomas J, Liu T, Raj D, London N, Tandeski T, Leachman SA, Lee RM, Grossman D. Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist. Oncogene. 2006;25:6968–6974. [PMC free article] [PubMed]
15. Thomas J, Liu T, Cotter M, Florell S, Robinette K, Hanks A, Grossman D. Melanocyte expression of Survivin promotes development and metastasis of UV-induced melanoma in HGF transgenic mice. Cancer Res. 2007 In press. [PMC free article] [PubMed]
16. Gradilone A, Gazzaniga P, Ribuffo D, Scarpa S, Cigna E, Vasaturo F, Bottoni U, Innocenzi D, Calvieri S, Scuderi N, Frati L, Agliano AM. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J Clin Oncol. 2003;21:306–312. [PubMed]
17. Takeuchi H, Morton DL, Elashoff D, Hoon DS. Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer. 2005;117:1032–1038. [PMC free article] [PubMed]
18. Hattori M, Sakamoto H, Satoh K, Yamamoto T. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett. 2001;169:155–164. [PubMed]
19. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J. 1999;344(Pt 2):305–311. [PubMed]
20. Xu Y, Fang F, Ludewig G, Jones G, Jones D. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 2004;23:527–537. [PubMed]
21. Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci. 2000;113(Pt 23):4363–4371. [PubMed]
22. Kang BH, Altieri DC. Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein. J Biol Chem. 2006;281:24721–24727. [PubMed]
23. Li Y, Xie M, Yang J, Yang D, Deng R, Wan Y, Yan B. The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter. Oncogene. 2006;25:3296–3306. [PubMed]
24. Cosgrave N, Hill AD, Young LS. Growth factor-dependent regulation of survivin by c-myc in human breast cancer. J Mol Endocrinol. 2006;37:377–390. [PubMed]
25. Zhu N, Gu L, Findley HW, Chen C, Dong JT, Yang L, Zhou M. KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem. 2006;281:14711–14718. [PubMed]
26. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S, Enkemann S, Eschrich S, Lee JH, Beam CA, Cheng J, Minton S, Muro-Cacho CA, Jove R. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 2006;12:11–19. [PubMed]
27. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem. 2006;281:25903–25914. [PMC free article] [PubMed]
28. Dasgupta P, Kinkade R, Joshi B, Decook C, Haura E, Chellappan S. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A. 2006;103:6332–6337. [PubMed]
29. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002;277:3247–3257. [PubMed]
30. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002;21:2613–2622. [PubMed]
31. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 1999;113:1076–1081. [PubMed]
32. Ahuja D, Saenz-Robles MT, Pipas JM. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene. 2005;24:7729–7745. [PubMed]
33. Wada K, Maesawa C, Akasaka T, Masuda T. Aberrant expression of the maspin gene associated with epigenetic modification in melanoma cells. J Invest Dermatol. 2004;122:805–811. [PubMed]
34. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580–584. [PubMed]
35. Xia F, Altieri DC. Mitosis-independent survivin gene expression in vivo and regulation by p53. Cancer Res. 2006;66:3392–3395. [PubMed]
36. Halaban R. Rb/E2F: a two-edged sword in the melanocytic system. Cancer Metastasis Rev. 2005;24:339–356. [PubMed]
37. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817–825. [PubMed]
38. Bartek J, Lukas J. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett. 2001;490:117–122. [PubMed]
39. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell. 1992;71:875–886. [PubMed]
40. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol. 2002;3:11–20. [PubMed]
41. Murga M, Fernandez-Capetillo O, Field SJ, Moreno B, Borlado LR, Fujiwara Y, Balomenos D, Vicario A, Carrera AC, Orkin SH, Greenberg ME, Zubiaga AM. Mutation of E2F2 in mice causes enhanced T lymphocyte proliferation, leading to the development of autoimmunity. Immunity. 2001;15:959–970. [PubMed]
42. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A. 2001;98:635–640. [PubMed]
43. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer. 2003;3:559–570. [PubMed]
44. Flores JF, Walker GJ, Glendening JM, Haluska FG, Castresana JS, Rubio MP, Pastorfide GC, Boyer LA, Kao WH, Bulyk ML, Barnhill RL, Hayward NK, Housman DE, Fountain JW. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res. 1996;56:5023–5032. [PubMed]
45. Vousden KH, Lu X. Live or let die: the cell’s response to p53. Nat Rev Cancer. 2002;2:594–604. [PubMed]
46. Lohr K, Moritz C, Contente A, Dobbelstein M. p21/CDKN1A mediates negative regulation of transcription by p53. J Biol Chem. 2003;278:32507–32516. [PubMed]
47. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA. Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem. 2004;279:40511–40520. [PubMed]
48. Li W, Sanki A, Karim RZ, Thompson JF, Soon Lee C, Zhuang L, McCarthy SW, Scolyer RA. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology. 2006;38:287–301. [PubMed]
49. Esteve PO, Chin HG, Pradhan S. Human maintenance DNA (cytosine-5)-methyltransferase and p53 modulate expression of p53-repressed promoters. Proc Natl Acad Sci U S A. 2005;102:1000–1005. [PubMed]
50. Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003;3:285–296. [PubMed]
51. Narita M, Nunez S, Heard E, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003;113:703–716. [PubMed]
52. Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, Fullen DR, Pointer JN, Gruber SB, Su LD, Nikiforov MA, Kaufman RJ, Bastian BC, Soengas MS. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol. 2006;8:1053–1063. [PubMed]
53. Wu J, Ling X, Pan D, Apontes P, Song L, Liang P, Altieri DC, Beerman T, Li F. Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem. 2005;280:9745–9751. [PMC free article] [PubMed]